A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Recruiting · NCT03847649 · Registry updated 2026-09-15

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies	cancer, neoplasm	Recruiting	Phase 2	2026-09-15		NCT03847649

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AstraZeneca	806
Canadian Cancer Trials Group	73

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
BCCA - Kelowna	Kelowna	Canada	10
BCCA - Vancouver	Vancouver	Canada	22
CHUM-Centre Hospitalier de l'Universite de Montreal	Montreal	Canada	20
Cross Cancer Institute	Edmonton	Canada	146
Juravinski Cancer Centre at Hamilton Health Sciences	Hamilton	Canada	60
Ottawa Hospital Research Institute	Ottawa	Canada	46
Regional Health Authority B, Zone 2	Saint John	Canada	7
Saskatoon Cancer Centre	Saskatoon	Canada	75
University Health Network	Toronto	Canada	52
Waterloo Regional Health Network (WRHN)	Kitchener	Canada	6
Windsor Regional Cancer Centre	Windsor	Canada	11